1 reports of this reaction
1.7% of all BEVACIZUMAB TNJN reports
#15 most reported adverse reaction
BLOOD POTASSIUM INCREASED is the #15 most commonly reported adverse reaction for BEVACIZUMAB TNJN, manufactured by Bio-Thera Solutions, Ltd.. There are 1 FDA adverse event reports linking BEVACIZUMAB TNJN to BLOOD POTASSIUM INCREASED. This represents approximately 1.7% of all 59 adverse event reports for this drug.
Patients taking BEVACIZUMAB TNJN who experience blood potassium increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD POTASSIUM INCREASED is a less commonly reported adverse event for BEVACIZUMAB TNJN, but still significant enough to appear in the safety profile.
In addition to blood potassium increased, the following adverse reactions have been reported for BEVACIZUMAB TNJN:
The following drugs have also been linked to blood potassium increased in FDA adverse event reports:
BLOOD POTASSIUM INCREASED has been reported as an adverse event in 1 FDA reports for BEVACIZUMAB TNJN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD POTASSIUM INCREASED accounts for approximately 1.7% of all adverse event reports for BEVACIZUMAB TNJN, making it a notable side effect.
If you experience blood potassium increased while taking BEVACIZUMAB TNJN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.